BMY Bristol-Myers Squibb Company Common Stock
$67,40
Prix · Aoû 25, 2026
Données fondamentales au Jul 30, 2026
Fourchette 52 semaines
$43–$69
95% of range
Note des analystes
HOLD
35 analysts
Objectif de cours
$66
P/E (TTM)
15.6
ROE
40.5%
Marge nette
14.6%
À propos de Bristol-Myers Squibb Company Common Stock Présentation de l'entreprise depuis Wikipedia
Bristol-Myers Squibb (BMS) est une entreprise pharmaceutique américaine née, en 1989, de la fusion entre Bristol-Myers Company, fondée en 1887 par William McLaren Bristol et John Ripley Myers à Clinton, et Squibb Corporation. C'est le dixième groupe pharmaceutique mondial.
Lire la suite
Bristol-Myers Squibb (BMS) est une entreprise pharmaceutique américaine née, en 1989, de la fusion entre Bristol-Myers Company, fondée en 1887 par William McLaren Bristol et John Ripley Myers (diplômés au Hamilton College) à Clinton (New York), et Squibb Corporation. C'est le dixième groupe pharmaceutique mondial.
Histoire
En 1989, deux entreprises américaines : Bristol Myers et Squibb fusionnent pour devenir
Bristol Myers Squibb (BMS)
En 1994, Bristol-Myers Squibb acquiert l'entreprise française UPSA, 4 ans après avoir pris 45 % de son capital
En 2001, Bristol-Myers Squibb scinde ses activités dans le matériel médical dans une nouvelle entreprise, Zimmer Holdings.
En 2009, Bristol-Myers Squibb se sépare de sa filiale de nutrition infantile, Mead Johnson, via une opération de spin-off, pour se concentrer sur la pharmacopée.
En février 2015, Bristol-Myers acquiert Flexus Biosciences, une entreprise pharmaceutique spécialisé dans l'oncologie, pour 1,25 milliard de dollars. En novembre 2015, Bristol-Myers annonce l'acquisition de Cardioxyl Pharmaceuticals, qui possède un traitement contre les arrêts cardiaques, pour 2,07 milliards de dollars. En décembre 2015, GlaxoSmithKline acquiert des médicaments en développement contre le VIH à Bristol-Myers Squibb pour 1,46 milliard de dollars.
En août 2017, Bristol-Myers annonce l'acquisition d'IFM Therapeutics, spécialisée dans l'oncologie, pour 300 millions de dollars.
En décembre 2018, Bristol-Myers annonce la vente de UPSA au groupe japonais Taisho Pharmaceutical (en) pour 1,6 milliard de dollars.
En janvier 2019, Bristol-Myers Squibb annonce l'acquisition de Celgene, entreprise spécialisée dans l'oncologie comme Bristol-Myers Squibb pour 74 milliards de dollars en plus d'une reprise de dette de 21 milliards de dollars.
La justice américaine accepte en janvier 2019 d'ouvrir un procès contre Bristol-Myers Squibb pour sa participation dans les années 1940 à un programme expérimental mené par les États-Unis au Guatemala. Près de 700 cobayes, parmi lesquels des enfants, avaient été contaminés sans leur consentement pour vérifier l’efficacité de la pénicilline sur les maladies sexuellement transmissible.
En octobre 2020, Bristol-Myers Squibb annonce l'acquisition de MyoKardia, spécialisée dans les maladies cardiovasculaires, pour 13 milliards de dollars.
En juin 2022, Bristol-Myers Squibb annonce l'acquisition de Turning Point Therapeutics, spécialisée dans l'oncologie, pour 4,1 milliards de dollars.
En octobre 2023, Bristol-Myers Squibb annonce pour 4,8 milliards de dollars l'acquisition de Mirati Therapeutics, spécialisée dans l'oncologie. En décembre 2023, Bristol Myers annonce l'acquisition de Karuna Therapeutics, spécialisée dans les médicaments contre la schizophrénie, pour 14 milliards de dollars. La même semaine, Bristol Myers annonce l'acquisition de RayzeBio, spécialisée dans l'oncologie, pour 4,1 milliards de dollars.
Présence en France
En 1990, le groupe implante un site de production à Meymac. L'usine est spécialisée dans la fabrication et le conditionnement de médicaments destinés à la prévention et au traitement du VIH et du sida, notamment le Videx ; y sont aussi fabriqués des médicaments pour traiter les maladies cardio-vasculaires, la douleur ou la dépression.
Après plusieurs mois d'incertitude, le 25 septembre 2008, la fermeture du site de Meymac et le transfert d'une partie de ses activités sur le site UPSA d'Agen sont confirmés pour 2010. Le site de Meymac est repris par les Laboratoires Salem France en septembre 2010.
Avec près de 3 000 collaborateurs et 1 milliard d’euros de chiffre d’affaires en 2009, Bristol-Myers Squibb France, dont le siège est à Rueil-Malmaison, est la première filiale du groupe hors États-Unis. Les usines UPSA à Agen sortent 50 % de la production mondiale du groupe et sont sa seule présence industrielle française.
Actionnaires
Liste des principaux actionnaires au 25 avril 2022 :
== Revenus & Émissions de CO2 ==
Source : Wikipedia, CC BY-SA 4.0 · Voir sur Wikipedia ↗
BMY Aperçu de l'action Prix, capitalisation boursière, P/E, EPS, ROE, dette/capitaux propres, fourchette sur 52 semaines
Prix
$67.40
Capitalisation Boursière
—
P/E (TTM)
15.6
BPA (TTM)
$3.46
Revenus (TTM)
$48.19B
Rendement div.
—
ROE
40.5%
Dette/Capitaux propres
2.5
Fourchette 52 semaines
$43 – $69
BMY Graphique du cours de l'action OHLCV quotidien avec indicateurs techniques — panoramique, zoom et personnalisez votre vue
Configure
Performance sur 10 ans Tendances du chiffre d'affaires, du bénéfice net, des marges et du BPA
Revenus et bénéfice net
$48.19B
2019-12-31
→
2025-12-31
BPA
$3.46
2019-12-31
→
2025-12-31
Flux de trésorerie libre
$12.85B
2019-12-31
→
2025-12-31
Marges
14.6%
2019-12-31
→
2020-12-31
Valorisation Ratios P/E, P/S, P/B, EV/EBITDA — l'action est-elle chère ou bon marché ?
Métrique
Tendance sur 5 ans
BMY
Médiane des pairs
P/E (TTM)
15.6
32.1
Rentabilité Marges brutes, d'exploitation et nettes ; ROE, ROA, ROIC
Métrique
Tendance sur 5 ans
BMY
Médiane des pairs
Net Profit Margin (Marge nette)
14.6%
13.0%
ROA
7.7%
6.4%
ROE
40.5%
15.1%
Santé financière Dette, liquidité, solvabilité — solidité du bilan
Métrique
Tendance sur 5 ans
BMY
Médiane des pairs
Debt / Equity (Dette / Capitaux propres)
2.5
—
Current Ratio (Ratio de liquidité)
1.3
1.6
Quick Ratio (Ratio de liquidité réduite)
0.8
—
Croissance Croissance du chiffre d'affaires, du BPA et du bénéfice net : Année/Année, TCAC 3 ans, TCAC 5 ans
Métrique
Tendance sur 5 ans
BMY
Médiane des pairs
Revenue YoY (Chiffre d'affaires YoY)
-0.22%
—
Revenue CAGR 3Y (CAGR du chiffre d'affaires 3 ans)
1.5%
—
Revenue CAGR 5Y (CAGR du chiffre d'affaires 5 ans)
2.5%
—
EPS YoY (BPA Année/Année)
30.9%
—
Net Income YoY (Bénéfice net YoY)
26.8%
—
Efficacité du capital Rotation des actifs, rotation des stocks, rotation des créances
Métrique
Tendance sur 5 ans
BMY
Médiane des pairs
Payout Ratio (Ratio de distribution)
71.5%
—
Dividendes Rendement, ratio de distribution, historique des dividendes, CAGR à 5 ans
Rendement du Dividende
—
Ratio de distribution
71.5%
CAGR des dividendes sur 5 ans
—
| Date ex-dividende | Montant |
|---|---|
| 2 juillet 2026 | $0,6300 |
| 2 avril 2026 | $0,6300 |
| 2 janvier 2026 | $0,6300 |
| 3 octobre 2025 | $0,6200 |
| 3 juillet 2025 | $0,6200 |
| 4 avril 2025 | $0,6200 |
| 3 janvier 2025 | $0,6200 |
| 4 octobre 2024 | $0,6000 |
| 5 juillet 2024 | $0,6000 |
| 4 avril 2024 | $0,6000 |
| 4 janvier 2024 | $0,6000 |
| 5 octobre 2023 | $0,5700 |
| 6 juillet 2023 | $0,5700 |
| 6 avril 2023 | $0,5700 |
| 5 janvier 2023 | $0,5700 |
| 6 octobre 2022 | $0,5400 |
| 30 juin 2022 | $0,5400 |
| 31 mars 2022 | $0,5400 |
| 6 janvier 2022 | $0,5400 |
| 30 septembre 2021 | $0,4900 |
BMY Consensus des analystes Opinions des analystes haussières et baissières, objectif de cours à 12 mois, potentiel de hausse
ACHAT
35 analystes
- Achat fort 6 17,1%
- Achat 8 22,9%
- Conserver 19 54,3%
- Vente 2 5,7%
- Vente forte 0 0,0%
Objectif de cours à 12 mois
24 analystes · 2026-08-24
Médiane
$68.00
Maintenant
$67.40
Bas
$40.00
Haut
$80.00
Objectif médian
$68.00
+0,9%
Objectif moyen
$66.21
-1,8%
Historique des bénéfices BPA réel vs estimation, surprise %, taux de succès, prochaine date de publication des résultats
Surprise Moyenne
0.25%
| Période | EPS Actual | BPA est. | Surprise |
|---|---|---|---|
| 30 juin 2026 | $2.04 | $1.60 | 0.44% |
| 31 mars 2026 | $1.58 | $1.43 | 0.15% |
| 31 décembre 2025 | $1.26 | $1.13 | 0.13% |
| 30 septembre 2025 | $1.63 | $1.52 | 0.11% |
| 30 juin 2025 | $1.46 | $1.08 | 0.38% |
| 31 mars 2025 | $1.80 | $1.51 | 0.29% |
Comparaison des pairs (sous-secteur GICS) Indicateurs clés par rapport aux pairs du secteur
| Ticker | Capitalisation Boursière | P/E | Revenus Année/Année | Marge Nette | ROE | Marge Brute |
|---|---|---|---|---|---|---|
| BMY | — | 15.6 | -0.22% | 14.6% | 40.5% | — |
| LLY | — | 46.8 | 44.7% | 31.7% | 101.2% | — |
| JNJ | — | 18.8 | 6.0% | 28.5% | 35.0% | 67.9% |
| MRK | — | 14.5 | 1.3% | 28.1% | 36.9% | — |
| PFE | — | 18.3 | -1.7% | 12.4% | 8.9% | — |
| RPRX | — | 21.7 | 5.1% | 32.4% | 8.0% | — |
| ZTS | $53.46B | 20.9 | 2.3% | 28.2% | 66.0% | — |
| VTRS | — | -4.2 | -3.0% | -24.6% | -23.2% | 35.1% |
| CORT | $3.69B | 42.4 | 12.8% | 13.1% | 15.5% | — |
| ELAN | $11.25B | -48.1 | 6.2% | -4.9% | -3.5% | 55.0% |
Fondamentaux complets Tous les indicateurs par an — compte de résultat, bilan, flux de trésorerie
Compte de résultat 17
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $48.19B | $48.30B | $45.01B | $46.16B | $46.38B | $42.52B | $26.14B | $22.56B | $20.78B | $19.43B | $16.56B | $15.88B | |
| Cost of Revenue | $13.94B | $13.97B | $10.69B | $10.14B | $9.94B | $11.77B | $8.08B | $6.47B | $6.01B | $4.97B | $3.91B | $3.93B | |
| Gross Profit | · | · | · | · | · | $30.75B | $18.07B | $16.09B | $14.68B | $14.48B | $12.65B | $11.95B | |
| R&D Expense | $9.95B | $11.16B | $9.30B | $9.51B | $10.20B | $10.05B | $6.15B | $6.33B | $6.47B | $5.01B | $5.92B | $4.53B | |
| SG&A Expense | $7.27B | $8.41B | $7.77B | $7.81B | $7.69B | $7.66B | $4.87B | $4.55B | $4.75B | $4.98B | $4.84B | $4.82B | |
| Operating Expenses | $38.87B | $56.68B | $36.57B | $38.45B | $38.29B | $49.39B | $21.17B | $16.59B | $15.64B | $13.51B | $14.48B | $13.50B | |
| Interest Expense | · | · | $1.17B | $1.23B | $1.33B | $1.42B | $656M | $183M | $196M | $167M | $184M | $203M | |
| Interest Income | $586M | $478M | $449M | $171M | $39M | $121M | $464M | $173M | $126M | $97M | $101M | $101M | |
| Other Non-op | $-674M | $-893M | $1.16B | $-576M | $720M | $2.31B | $-938M | $854M | $1.69B | $1.45B | $187M | $-210M | |
| Pretax Income | $9.33B | $-8.38B | $8.44B | $7.71B | $8.10B | $-6.87B | $4.97B | $5.97B | $5.13B | $5.92B | $2.08B | $2.38B | |
| Income Tax | $2.27B | $554M | $400M | $1.37B | $1.08B | $2.12B | $1.51B | $1.02B | $4.16B | $1.41B | $446M | $352M | |
| Net Income | $7.05B | $-8.95B | $8.03B | $6.33B | $6.99B | $-9.02B | $3.44B | $4.92B | $1.01B | $4.46B | $1.56B | $2.00B | |
| EPS (Basic) | $3.47 | $-4.41 | $3.88 | $2.97 | $3.15 | $-3.99 | $2.02 | $3.01 | $0.61 | $2.67 | $0.94 | $1.21 | |
| EPS (Diluted) | $3.46 | $-4.41 | $3.86 | $2.95 | $3.12 | $-3.99 | $2.01 | $3.01 | $0.61 | $2.65 | $0.93 | $1.20 | |
| Shares (Basic) | 2,034,000,000 | 2,027,000,000 | 2,069,000,000 | 2,130,000,000 | 2,221,000,000 | 2,258,000,000 | 1,705,000,000 | 1,633,000,000 | 1,645,000,000 | 1,671,000,000 | 1,667,000,000 | 1,657,000,000 | |
| Shares (Diluted) | 2,039,000,000 | 2,027,000,000 | 2,078,000,000 | 2,146,000,000 | 2,245,000,000 | 2,258,000,000 | 1,712,000,000 | 1,637,000,000 | 1,652,000,000 | 1,680,000,000 | 1,679,000,000 | 1,670,000,000 | |
| EBITDA | $4.01B | $9.60B | $9.76B | $10.28B | $10.69B | $10.38B | $1.75B | $637M | $789M | $382M | $376M | $467M |
Bilan 31
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $10.21B | $10.35B | $11.46B | $9.12B | $13.98B | $14.55B | $12.35B | $6.91B | $5.42B | $4.24B | $2.38B | $5.57B | |
| Short-term Investments | · | · | · | $130M | $2.99B | $1.28B | $3.05B | $1.85B | $1.39B | $2.11B | $1.89B | $1.86B | |
| Receivables | $9.59B | $9.01B | $8.88B | $8.15B | $7.98B | $7.22B | $6.48B | $4.64B | $4.35B | $3.77B | $2.95B | $2.10B | |
| Inventory | $2.69B | $2.56B | $2.66B | $2.34B | $2.10B | $2.07B | $4.29B | $1.20B | $1.17B | $1.24B | $1.22B | $1.56B | |
| Prepaid Expense | · | · | · | · | · | · | · | · | $576M | $570M | $625M | $470M | |
| Other Current Assets | $4.61B | $5.62B | $5.91B | $5.79B | $4.83B | $3.79B | $1.98B | $2.02B | $576M | $570M | $625M | $470M | |
| Current Assets | $29.39B | $29.78B | $31.77B | $27.27B | $33.26B | $30.19B | $29.35B | $17.72B | $14.85B | $13.70B | $10.41B | $14.61B | |
| PP&E (Net) | $7.54B | $7.14B | $6.65B | $6.25B | $6.05B | $5.89B | $6.25B | $5.03B | $5.00B | $4.98B | $4.41B | $4.42B | |
| PP&E (Gross) | $12.84B | $12.09B | $11.45B | $10.42B | $10.08B | $9.47B | $10.21B | $8.85B | $8.99B | $9.17B | $8.63B | $9.07B | |
| Accum. Depreciation | $5.29B | $4.95B | $4.80B | $4.16B | $4.03B | $3.58B | $3.96B | $3.82B | $3.99B | $4.19B | $4.22B | $4.65B | |
| Goodwill | $21.75B | $21.72B | $21.17B | $21.15B | $20.50B | $20.55B | $22.49B | $6.54B | $6.86B | $6.88B | $6.88B | $7.03B | |
| Intangibles | $19.10B | $23.31B | $27.07B | $35.86B | $42.53B | $53.24B | $63.97B | $1.09B | $1.21B | $1.39B | $1.42B | $1.75B | |
| Other Non-current Assets | $6.47B | $6.11B | $5.37B | $4.94B | $5.54B | $7.02B | $6.60B | $2.02B | $1.53B | $1.05B | $1.12B | $621M | |
| Total Assets | $90.04B | $92.60B | $95.16B | $96.82B | $109.31B | $118.48B | $129.94B | $34.99B | $33.55B | $33.71B | $31.75B | $33.75B | |
| Accounts Payable | $3.58B | $3.60B | $3.26B | $3.04B | $2.95B | $2.71B | $2.44B | $1.89B | $2.25B | $1.66B | $1.56B | $2.49B | |
| Accrued Liabilities | · | · | · | · | · | · | · | $6.49B | $6.01B | $5.27B | $4.74B | $2.46B | |
| Short-term Debt | $2.26B | $2.05B | $3.12B | $4.26B | $4.95B | $2.34B | $3.35B | $1.70B | $987M | $109M | $139M | $590M | |
| Current Liabilities | $23.42B | $23.77B | $22.26B | $21.89B | $21.87B | $19.08B | $18.30B | $10.65B | $9.56B | $8.84B | $8.02B | $8.46B | |
| Capital Leases | $1.83B | $1.37B | $1.53B | $1.26B | $874M | $833M | $672M | $0 | · | · | · | · | |
| Deferred Tax | $222M | $369M | $338M | $2.17B | $4.50B | $5.41B | $6.45B | $19M | $45M | $47M | $31M | $60M | |
| Other Non-current Liabilities | $5.04B | $4.47B | $6.42B | $6.59B | $7.33B | $7.78B | $10.10B | $4.54B | $1.16B | $1.28B | $1.43B | $618M | |
| Total Liabilities | $71.53B | $76.22B | $65.67B | $65.70B | $73.31B | $80.60B | $78.25B | $20.86B | $21.70B | $17.36B | $17.32B | $18.77B | |
| Long-term Debt | $44.83B | $49.43B | $39.53B | $38.95B | $44.37B | $50.34B | $46.15B | $6.89B | $6.97B | $6.46B | · | · | |
| Total Debt | $47.09B | $51.48B | $42.65B | $43.22B | $49.32B | $52.68B | $49.50B | $8.60B | $7.49B | $7.46B | $6.69B | $7.83B | |
| Common Stock | · | · | · | $292M | $292M | $292M | $292M | $221M | $221M | $221M | $221M | $221M | |
| Paid-in Capital | $46.39B | $46.02B | $45.68B | $45.16B | $44.36B | $44.33B | $43.71B | $2.08B | $1.90B | $1.73B | $1.46B | $1.51B | |
| Retained Earnings | $16.90B | $14.91B | $28.77B | $25.50B | $23.82B | $21.28B | $34.47B | $34.06B | $31.16B | $33.51B | $31.61B | $32.54B | |
| Treasury Stock | $43.58B | $43.66B | $43.77B | $38.62B | $31.26B | $26.24B | $25.36B | $19.57B | $19.25B | $16.78B | $16.56B | $16.99B | |
| AOCI | $-1.52B | $-1.24B | $-1.55B | $-1.28B | $-1.27B | $-1.84B | $-1.52B | $-2.76B | $-2.29B | $-2.50B | $-2.47B | $-2.42B | |
| Stockholders' Equity | $18.47B | $16.34B | $29.43B | $31.06B | $35.95B | $37.82B | $51.60B | $14.03B | $11.74B | $16.18B | $14.27B | $14.85B | |
| Liabilities + Equity | $90.04B | $92.60B | $95.16B | $96.82B | $109.31B | $118.48B | $129.94B | $34.99B | $33.55B | $33.71B | $31.75B | $33.75B |
Flux de trésorerie 19
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $4.01B | $9.60B | $9.76B | $10.28B | $10.69B | $10.38B | $1.75B | $637M | $789M | $382M | $376M | $467M | |
| Stock-based Comp | $553M | $507M | $518M | $457M | $583M | $779M | $441M | $221M | $199M | $205M | $235M | $213M | |
| Deferred Tax | $-965M | $-2.09B | $-3.29B | $-2.74B | $-1.39B | $983M | $-924M | $45M | $453M | $-204M | $-347M | $-542M | |
| Amort. of Intangibles | $3.50B | $9.00B | $9.20B | $9.70B | $10.20B | $9.90B | $1.30B | $198M | $190M | $178M | $183M | $286M | |
| Restructuring | $563M | $635M | $365M | $75M | $169M | $530M | $301M | $131M | $293M | $109M | $118M | $163M | |
| Other Non-cash | $3.50B | $16.12B | $-1.16B | $-1.26B | $-663M | $10.93B | $3.37B | $76M | $2.27B | $-1.99B | $3M | $1.01B | |
| Operating Cash Flow | $14.16B | $15.19B | $13.86B | $13.07B | $16.21B | $14.05B | $8.21B | $7.07B | $5.28B | $3.06B | $2.10B | $3.15B | |
| CapEx | $1.31B | $1.25B | $1.21B | $1.12B | $973M | $753M | $836M | $951M | $1.05B | $1.22B | $820M | $526M | |
| Investing Cash Flow | $-4.13B | $-21.35B | $-2.29B | $-1.06B | $-538M | $-10.86B | $-9.91B | $-2.00B | $-66M | $1.48B | $-1.57B | $1.22B | |
| Debt Issued | $5.74B | $12.88B | $4.46B | $5.93B | $0 | $6.95B | $26.78B | $0 | $1.49B | $0 | $1.27B | · | |
| Net Debt Issued | $-5.20B | $10.01B | $576M | $-5.50B | $-6.02B | $4.20B | $17.52B | $-5M | $264M | $-15M | $-689M | $-676M | |
| Stock Repurchased | $0 | $0 | $5.16B | $8.00B | $6.29B | $1.55B | $7.30B | $320M | $2.47B | $231M | · | · | |
| Net Stock Activity | $0 | $0 | $-5.16B | $-8.00B | $-6.29B | $-1.55B | $-7.30B | $-320M | $-2.47B | $-231M | · | · | |
| Dividends Paid | $5.04B | $4.86B | $4.74B | $4.63B | $4.40B | $4.08B | $2.68B | $2.61B | $2.58B | $2.55B | $2.48B | $2.40B | |
| Financing Cash Flow | $-10.35B | $5.13B | $-9.42B | $-16.96B | $-16.22B | $-1.15B | $7.62B | $-3.54B | $-4.08B | $-2.65B | $-3.62B | $-2.44B | |
| Net Change in Cash | $-129M | $-1.17B | $2.19B | $-4.99B | $-657M | $2.15B | $5.91B | $1.49B | $1.18B | $1.85B | $-3.19B | $1.99B | |
| Taxes Paid | $3.26B | $3.90B | $4.30B | $5.40B | $3.50B | $3.40B | $1.50B | $747M | $546M | $2.00B | $577M | $544M | |
| Free Cash Flow | $12.85B | $13.94B | $12.65B | $11.95B | $15.23B | $13.30B | $7.23B | $4.99B | $4.22B | $1.64B | $1.01B | $2.62B | |
| Levered FCF | · | · | $11.54B | $10.93B | $14.08B | $11.44B | $6.77B | $4.84B | $4.18B | $1.51B | $868M | $2.45B |
Rentabilité 6
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | · | · | · | 72.3% | 69.1% | 71.0% | 70.8% | 74.5% | 76.4% | 75.2% | |
| Net Margin | 14.6% | -18.5% | 17.8% | 13.7% | 15.1% | -21.2% | 13.2% | 21.8% | 4.9% | 22.9% | 9.4% | 12.6% | |
| Pretax Margin | 19.4% | -17.3% | 18.8% | 16.7% | 17.5% | -16.2% | 19.0% | 26.5% | 24.7% | 30.4% | 12.5% | 15.0% | |
| EBITDA Margin | 8.3% | 19.9% | 21.7% | 22.3% | 23.0% | 24.4% | 6.7% | 2.8% | 3.8% | 2.0% | 2.3% | 2.9% | |
| ROA | 7.7% | -9.5% | 8.4% | 6.1% | 6.1% | -7.4% | 3.7% | 14.3% | 3.0% | 13.2% | 4.9% | 6.0% | |
| ROE | 40.5% | -39.1% | 26.5% | 18.9% | 19.0% | -20.2% | 10.5% | 38.2% | 7.2% | 29.3% | 10.8% | 13.4% |
Liquidité et Solvabilité 4
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.3 | 1.3 | 1.4 | 1.2 | 1.5 | 1.6 | 1.6 | 1.6 | 1.6 | 1.6 | 1.3 | 1.7 | |
| Quick Ratio | 0.8 | 0.8 | 0.9 | 0.8 | 1.1 | 1.2 | 1.2 | 1.3 | 1.2 | 1.1 | 0.9 | 1.1 | |
| Debt / Equity | 2.5 | 3.2 | 1.4 | 1.4 | 1.4 | 1.4 | 1.0 | 0.6 | 0.6 | 0.5 | 0.5 | 0.5 | |
| LT Debt / Equity | 2.3 | 2.9 | 1.2 | 1.1 | 1.1 | 1.3 | 0.8 | 0.4 | 0.6 | 0.4 | 0.5 | 0.5 |
Efficacité 3
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | 0.5 | 0.5 | 0.4 | 0.4 | 0.3 | 0.3 | 0.7 | 0.6 | 0.6 | 0.5 | 0.5 | |
| Inventory Turnover | 5.3 | 5.4 | 4.3 | 4.6 | 4.8 | 3.7 | 2.9 | 5.5 | 5.0 | 4.0 | 2.8 | 2.6 | |
| Receivables Turnover | 5.2 | 5.4 | 5.3 | 5.7 | 6.1 | 6.2 | 4.7 | 5.0 | 5.1 | 5.8 | 6.6 | 8.4 |
Taux de croissance 8
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -0.22% | 7.3% | -2.5% | -0.49% | 9.1% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 1.5% | 1.4% | 1.9% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 2.5% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | · | · | 30.9% | -5.5% | · | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 5.5% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | · | · | 26.8% | -9.5% | · | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 3.7% | · | · | · | · | · | · | · | · | · | · | · | |
| Dividend CAGR 5Y | 4.4% | · | · | · | · | · | · | · | · | · | · | · |
Valorisation (TTM) 6
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $48.19B | $48.30B | $45.01B | $46.16B | $46.38B | $42.52B | $26.14B | $22.56B | $20.78B | $19.43B | $16.56B | $15.88B | |
| Net Income TTM | $7.05B | $-8.95B | $8.03B | $6.33B | $6.99B | $-9.02B | $3.44B | $4.92B | $1.01B | $4.46B | $1.56B | $2.00B | |
| P/E | 15.6 | -12.8 | 13.3 | 24.4 | 20.0 | -15.5 | 31.9 | 17.3 | 100.5 | 22.1 | 74.0 | 49.2 | |
| Earnings Yield | 6.4% | -7.8% | 7.5% | 4.1% | 5.0% | -6.4% | 3.1% | 5.8% | 1.0% | 4.5% | 1.4% | 2.0% | |
| Payout Ratio | 71.5% | -54.4% | 59.1% | 73.2% | 62.8% | -45.2% | 77.9% | 53.1% | 255.9% | 57.1% | 158.3% | 119.7% | |
| Annual Payout | $5.04B | $4.86B | $4.74B | $4.63B | $4.40B | $4.08B | $2.68B | $2.61B | $2.58B | $2.55B | $2.48B | $2.40B |
Compte de résultat 16
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12.97B | $11.49B | $12.50B | $12.22B | $12.27B | $11.20B | $12.34B | $11.89B | $12.20B | $11.87B | $11.48B | $10.97B | $11.23B | $11.34B | $11.41B | $11.22B | |
| Cost of Revenue | $3.73B | $3.42B | $4.10B | $3.44B | $3.37B | $3.03B | $4.81B | $2.96B | $3.27B | $2.93B | $2.75B | $2.51B | $2.88B | $2.57B | $2.59B | $2.35B | |
| R&D Expense | $2.96B | $2.65B | $2.59B | $2.53B | $2.58B | $2.26B | $3.19B | $2.37B | $2.90B | $2.69B | $2.48B | $2.24B | $2.26B | $2.32B | $2.51B | $2.42B | |
| SG&A Expense | $1.83B | $1.62B | $2.18B | $1.79B | $1.71B | $1.58B | $2.14B | $1.98B | $1.93B | $2.37B | $2.07B | $2.00B | $1.93B | $1.76B | $2.27B | $1.93B | |
| Operating Expenses | $8.89B | $8.25B | $11.03B | $9.11B | $10.50B | $8.23B | $12.17B | $10.22B | $10.91B | $23.38B | $9.80B | $8.83B | $9.37B | $8.57B | $9.55B | $9.01B | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $425M | · | $280M | $282M | $288M | · | $299M | |
| Interest Income | $101M | $104M | $148M | $161M | $139M | $138M | $114M | $94M | $87M | $183M | $145M | $107M | $95M | $102M | $82M | $52M | |
| Other Non-op | $61M | $-32M | $51M | $108M | $-494M | $-339M | $-305M | $-234M | $-273M | $-81M | $371M | $258M | $116M | $413M | $217M | $140M | |
| Pretax Income | $4.09B | $3.24B | $1.47B | $3.11B | $1.77B | $2.97B | $175M | $1.68B | $1.29B | $-11.52B | $1.67B | $2.14B | $1.86B | $2.77B | $1.86B | $2.21B | |
| Income Tax | $770M | $561M | $384M | $919M | $460M | $509M | $99M | $461M | $-398M | $392M | $-88M | $203M | $-218M | $503M | $-166M | $601M | |
| Net Income | $3.32B | $2.68B | $1.09B | $2.20B | $1.31B | $2.46B | $72M | $1.21B | $1.68B | $-11.91B | $1.76B | $1.93B | $2.07B | $2.26B | $2.02B | $1.61B | |
| EPS (Basic) | $1.62 | $1.31 | $0.54 | $1.08 | $0.64 | $1.21 | $0.05 | $0.60 | $0.83 | $-5.89 | $0.87 | $0.94 | $0.99 | $1.08 | $0.95 | $0.75 | |
| EPS (Diluted) | $1.62 | $1.31 | $0.54 | $1.08 | $0.64 | $1.20 | $0.05 | $0.60 | $0.83 | $-5.89 | $0.87 | $0.93 | $0.99 | $1.07 | $0.95 | $0.75 | |
| Shares (Basic) | 2,042,000,000 | 2,038,000,000 | -4,068,000,000 | 2,036,000,000 | 2,035,000,000 | 2,031,000,000 | -4,051,000,000 | 2,028,000,000 | 2,027,000,000 | 2,023,000,000 | -4,180,000,000 | 2,057,000,000 | 2,093,000,000 | 2,099,000,000 | -4,282,000,000 | 2,133,000,000 | |
| Shares (Diluted) | 2,048,000,000 | 2,047,000,000 | -4,078,000,000 | 2,039,000,000 | 2,038,000,000 | 2,040,000,000 | -4,056,000,000 | 2,031,000,000 | 2,029,000,000 | 2,023,000,000 | -4,201,000,000 | 2,064,000,000 | 2,102,000,000 | 2,113,000,000 | -4,315,000,000 | 2,148,000,000 | |
| EBITDA | · | $594M | · | · | · | $1.01B | · | · | · | $2.53B | · | · | · | $2.43B | · | · |
Bilan 29
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $8.72B | $9.57B | $10.21B | $15.73B | $12.60B | $10.88B | $10.35B | $7.89B | $6.29B | $9.33B | · | $7.51B | $8.37B | $8.99B | · | $7.73B | |
| Short-term Investments | · | · | · | · | · | · | · | · | · | · | · | $171M | $358M | $274M | · | $1.29B | |
| Receivables | $9.08B | $7.95B | $9.59B | $9.62B | $9.71B | $9.06B | $9.01B | $9.32B | $9.75B | $8.83B | · | $8.41B | $8.12B | $7.85B | · | $8.02B | |
| Inventory | $2.74B | $2.76B | $2.69B | $2.76B | $2.74B | $2.67B | $2.56B | $3.33B | $3.08B | $2.98B | · | $2.44B | $2.36B | $2.60B | · | $2.07B | |
| Other Current Assets | $4.22B | $4.60B | $4.61B | $4.95B | $5.47B | $5.53B | $5.62B | $5.62B | $5.74B | $5.57B | · | $7.21B | $6.87B | $5.16B | · | $6.08B | |
| Current Assets | $28.58B | $27.21B | $29.39B | $35.63B | $33.22B | $30.78B | $29.78B | $28.07B | $26.89B | $28.67B | · | $27.63B | $28.07B | $27.09B | · | $26.80B | |
| PP&E (Net) | $7.79B | $7.66B | $7.54B | $7.35B | $7.37B | $7.21B | $7.14B | $6.90B | $6.84B | $6.75B | · | $6.48B | $6.36B | $6.28B | · | $6.04B | |
| PP&E (Gross) | $13.34B | $13.09B | $12.84B | $12.54B | $12.68B | $12.32B | $12.09B | $11.74B | $11.93B | $11.69B | · | $11.13B | $10.83B | $10.52B | · | $10.17B | |
| Accum. Depreciation | $5.55B | $5.43B | $5.29B | $5.20B | $5.31B | $5.11B | $4.95B | $4.84B | $5.09B | $4.94B | · | $4.65B | $4.48B | $4.24B | · | $4.14B | |
| Goodwill | $21.74B | $21.74B | $21.75B | $21.75B | $21.78B | $21.74B | $21.72B | $21.75B | $21.73B | $21.74B | $21.17B | $21.15B | $21.16B | $21.16B | $21.15B | $21.11B | |
| Intangibles | $17.39B | $18.24B | $19.10B | $20.46B | $21.38B | $22.49B | $23.31B | $26.96B | $29.43B | $32.76B | · | $28.95B | $31.30B | $33.57B | · | $38.18B | |
| Other Non-current Assets | $6.38B | $6.08B | $6.47B | $6.33B | $5.94B | $5.87B | $6.11B | $6.04B | $6.07B | $6.02B | · | $5.21B | $5.02B | $4.87B | · | $4.75B | |
| Total Assets | $87.63B | $86.48B | $90.04B | $96.89B | $94.68B | $92.43B | $92.60B | $93.67B | $94.65B | $99.03B | · | $91.26B | $93.49B | $94.28B | · | $98.20B | |
| Accounts Payable | $4.16B | $4.23B | $3.58B | $4.29B | $5.43B | $4.00B | $3.60B | $3.47B | $3.75B | $3.54B | · | $2.81B | $3.07B | $3.19B | · | $2.60B | |
| Short-term Debt | $1.03B | $2.31B | $2.26B | $4.51B | $4.71B | $3.55B | $2.05B | $1.08B | $3.53B | $6.19B | · | $5.47B | $3.02B | $2.75B | · | $2.13B | |
| Current Liabilities | $18.66B | $19.16B | $23.42B | $28.14B | $27.53B | $24.07B | $23.77B | $22.64B | $23.27B | $25.82B | · | $23.46B | $20.15B | $19.09B | · | $18.93B | |
| Capital Leases | $1.73B | $1.77B | $1.83B | $1.85B | $1.55B | $1.36B | $1.37B | $1.48B | $1.44B | $1.56B | · | $1.51B | $1.34B | $1.37B | · | $845M | |
| Deferred Tax | $222M | $211M | $222M | $225M | $247M | $276M | $369M | $430M | $461M | $442M | · | $399M | $751M | $1.57B | · | $2.88B | |
| Other Non-current Liabilities | $4.34B | $4.85B | $5.04B | $5.46B | $4.94B | $4.48B | $4.47B | $4.73B | $4.99B | $6.73B | · | $6.20B | $5.90B | $6.66B | · | $6.68B | |
| Total Liabilities | $65.31B | $66.37B | $71.53B | $78.29B | $77.19B | $74.98B | $76.22B | $76.47B | $77.58B | $82.48B | · | $62.20B | $61.46B | $62.40B | · | $65.46B | |
| Long-term Debt | $42.86B | $44.14B | $44.83B | $48.72B | $48.95B | $49.51B | $49.43B | $49.55B | $51.95B | $52.36B | · | $37.01B | $37.07B | $37.33B | · | $38.87B | |
| Total Debt | $43.89B | $46.45B | · | $53.23B | $53.66B | $53.06B | · | $50.62B | $55.48B | $58.55B | · | $42.48B | $40.09B | $40.08B | · | $41.00B | |
| Common Stock | · | · | · | · | · | · | · | · | · | · | · | · | $292M | $292M | · | $292M | |
| Paid-in Capital | $46.50B | $46.37B | $46.39B | $46.27B | $46.13B | $46.01B | $46.02B | $45.90B | $45.77B | $45.66B | · | $44.85B | $45.30B | $45.14B | · | $44.96B | |
| Retained Earnings | $20.32B | $18.29B | $16.90B | $17.09B | $16.15B | $16.11B | $14.91B | $16.10B | $16.10B | $15.64B | · | $28.22B | $27.45B | $26.57B | · | $24.68B | |
| Treasury Stock | $43.50B | $43.52B | $43.58B | $43.59B | $43.59B | $43.60B | $43.66B | $43.67B | $43.69B | $43.70B | · | $43.08B | $39.68B | $38.81B | · | $36.41B | |
| AOCI | $-1.29B | $-1.37B | $-1.52B | $-1.51B | $-1.55B | $-1.42B | $-1.24B | $-1.47B | $-1.46B | $-1.40B | · | $-1.29B | $-1.39B | $-1.37B | · | $-841M | |
| Stockholders' Equity | $22.32B | $20.07B | $18.47B | $18.55B | $17.43B | $17.39B | $16.34B | $17.14B | $17.02B | $16.49B | · | $29.00B | $31.97B | $31.82B | · | $32.67B | |
| Liabilities + Equity | $87.63B | $86.48B | $90.04B | $96.89B | $94.68B | $92.43B | $92.60B | $93.67B | $94.65B | $99.03B | · | $91.26B | $93.49B | $94.28B | · | $98.20B |
Flux de trésorerie 19
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $594M | $594M | $977M | $1.01B | $1.01B | $1.01B | $1.88B | $2.59B | $2.60B | $2.53B | $2.46B | $2.44B | $2.43B | $2.43B | $2.52B | $2.59B | |
| Stock-based Comp | $135M | $146M | $133M | $139M | $137M | $144M | $120M | $129M | $125M | $133M | $127M | $132M | $137M | $122M | $119M | $115M | |
| Deferred Tax | $-195M | $161M | $-392M | $-359M | $-437M | $223M | $-791M | $-256M | $-331M | $-711M | $-1.33B | $-327M | $-1.09B | $-548M | $-624M | $-645M | |
| Amort. of Intangibles | $471M | $472M | $906M | $867M | $864M | $863M | $1.80B | $2.40B | $2.40B | $2.40B | $2.30B | $2.30B | $2.30B | $2.30B | $2.30B | $2.50B | |
| Restructuring | $56M | $5M | $132M | $75M | $223M | $133M | $77M | $78M | $260M | $220M | $44M | $141M | $113M | $67M | $15M | $17M | |
| Other Non-cash | · | $-2.47B | · | · | · | $-1.88B | · | · | · | $12.79B | · | · | · | $-1.29B | · | · | |
| Operating Cash Flow | $3.39B | $1.10B | $1.97B | $6.31B | $3.92B | $1.95B | $4.44B | $5.59B | $2.33B | $2.83B | $4.25B | $4.75B | $1.89B | $2.97B | $3.31B | $3.69B | |
| CapEx | $305M | $347M | $370M | $320M | $361M | $260M | $378M | $324M | $262M | $284M | $330M | $342M | $259M | $278M | $346M | $247M | |
| Investing Cash Flow | $-1.61B | $-131M | $-1.46B | $-1.70B | $-473M | $-499M | $-196M | $-219M | $-1.32B | $-19.62B | $-1.35B | $-410M | $-329M | $-210M | $1.21B | $-2.08B | |
| Debt Issued | · | · | $5.74B | $0 | $0 | $0 | $0 | $0 | $0 | $12.88B | · | · | · | · | $26M | $0 | |
| Net Debt Issued | · | $-500M | · | · | · | $0 | · | · | · | $0 | · | · | · | $-1.64B | · | · | |
| Stock Repurchased | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $0 | $4.00B | $905M | $250M | $2.42B | $701M | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | $0 | · | · | · | $-250M | · | $-701M | |
| Dividends Paid | $1.29B | $1.28B | $1.26B | $1.26B | $1.26B | $1.26B | $1.22B | $1.22B | $1.22B | $1.21B | $1.16B | $1.19B | $1.20B | $1.20B | $1.15B | $1.15B | |
| Financing Cash Flow | $-2.63B | $-1.56B | $-6.03B | $-1.49B | $-1.84B | $-993M | $-1.64B | $-3.85B | $-4.02B | $14.64B | $967M | $-5.16B | $-2.17B | $-3.05B | $-3.25B | $-4.54B | |
| Net Change in Cash | $-861M | $-635M | $-5.51B | $3.12B | $1.74B | $528M | $2.45B | $1.60B | $-3.04B | $-2.19B | $3.95B | $-857M | $-623M | $-277M | $1.37B | $-3.00B | |
| Taxes Paid | · | $239M | $1.06B | $400M | $1.56B | $235M | $800M | $1.00B | $1.91B | $187M | $200M | $1.00B | $2.95B | $149M | $1.50B | $1.20B | |
| Free Cash Flow | · | $757M | · | · | · | $1.69B | · | · | · | $2.55B | · | · | · | $2.69B | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $2.11B | · | · | · | $2.46B | · | · |
Rentabilité 5
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 25.6% | 23.3% | · | 18.0% | 10.7% | 21.9% | · | 10.2% | 13.8% | -100.4% | · | 17.6% | 18.5% | 20.0% | · | 14.3% | |
| Pretax Margin | 31.5% | 28.2% | · | 25.5% | 14.4% | 26.5% | · | 14.1% | 10.5% | -97.1% | · | 19.5% | 16.6% | 24.4% | · | 19.7% | |
| EBITDA Margin | · | 5.2% | · | · | · | 9.0% | · | · | · | 21.3% | · | · | · | 21.4% | · | · | |
| ROA | 3.6% | 3.0% | · | 2.3% | 1.4% | 2.6% | · | 1.3% | 1.8% | -12.3% | · | 2.0% | 2.1% | 2.3% | · | 1.5% | |
| ROE | 16.7% | 14.3% | · | 12.3% | 7.6% | 14.5% | · | 5.2% | 6.9% | -49.3% | · | 6.2% | 6.4% | 7.1% | · | 4.6% |
Liquidité et Solvabilité 4
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.5 | 1.4 | · | 1.3 | 1.2 | 1.3 | · | 1.2 | 1.2 | 1.1 | · | 1.2 | 1.4 | 1.4 | · | 1.4 | |
| Quick Ratio | 1.0 | 0.9 | · | 0.9 | 0.8 | 0.8 | · | 0.8 | 0.7 | 0.7 | · | 0.7 | 0.8 | 0.9 | · | 0.9 | |
| Debt / Equity | 2.0 | 2.3 | · | 2.9 | 3.1 | 3.1 | · | 3.0 | 3.3 | 3.6 | · | 1.5 | 1.3 | 1.3 | · | 1.3 | |
| LT Debt / Equity | 1.9 | 2.1 | · | 2.4 | 2.6 | 2.7 | · | 2.8 | 2.9 | 3.0 | · | 1.1 | 1.1 | 1.1 | · | 1.1 |
Efficacité 3
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Inventory Turnover | 1.4 | 1.3 | · | 1.1 | 1.2 | 1.1 | · | 1.0 | 1.2 | 1.0 | · | 1.1 | 1.3 | 1.1 | · | 1.1 | |
| Receivables Turnover | 1.4 | 1.4 | · | 1.3 | 1.3 | 1.3 | · | 1.3 | 1.4 | 1.4 | · | 1.3 | 1.4 | 1.5 | · | 1.4 |
Valorisation (TTM) 5
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $48.95B | $47.18B | · | $47.58B | $47.56B | $47.16B | · | $46.92B | $46.26B | $45.39B | · | $44.75B | $45.67B | $46.09B | · | $46.38B | |
| Net Income TTM | $9.51B | $8.64B | · | $7.18B | $6.66B | $-6.56B | · | $-7.09B | $-6.23B | $-5.65B | · | $7.87B | $7.36B | $6.57B | · | $5.85B | |
| P/E | 12.4 | 14.3 | · | 12.8 | 14.2 | -18.7 | · | -14.7 | -13.2 | -18.7 | · | 15.5 | 18.4 | 22.6 | · | 26.4 | |
| Earnings Yield | 8.1% | 7.0% | · | 7.8% | 7.1% | -5.3% | · | -6.8% | -7.6% | -5.3% | · | 6.4% | 5.4% | 4.4% | · | 3.8% | |
| Payout Ratio | · | 47.9% | · | · | · | 51.2% | · | · | · | -10.2% | · | · | · | 52.9% | · | · |
États financiers Compte de résultat, bilan, flux de trésorerie — annuel, sur les 5 dernières années
Compte de résultat
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Revenu | $48.19B | $48.30B | $45.01B | $46.16B | $46.38B |
| Résultat net | $7.05B | $-8.95B | $8.03B | $6.33B | $6.99B |
| BPA dilué | $3.46 | $-4.41 | $3.86 | $2.95 | $3.12 |
Bilan
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Dette / Capitaux propres | 2.5 | 3.2 | 1.4 | 1.4 | 1.4 |
| Ratio de liquidité | 1.3 | 1.3 | 1.4 | 1.2 | 1.5 |
| Ratio de liquidité réduite | 0.8 | 0.8 | 0.9 | 0.8 | 1.1 |
Flux de trésorerie
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Flux de trésorerie libre | $12.85B | $13.94B | $12.65B | $11.95B | $15.23B |
Dernières actualités Actualités récentes mentionnant cette entreprise
- Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen?
- Bristol Myers Squibb to build $2.3 billion Houston campus
- Exclusive-'No discussions' over AstraZeneca-Bristol Myers deal, senior source says
- The $400 Billion Reason Bristol-Myers Squibb (BMY) Stock Is Up Today
- Bristol Myers Squibb Stock Jumps on Reported Merger Talks With AstraZeneca
- $400 Billion Pharma Megadeal? Jefferies Calls Potential AstraZeneca-Bristol Myers Merger A "Head Scratcher"
- AstraZeneca shares drop 7% after report on $400 billion merger talks with Bristol Myers Squibb
- Bill Ackman Runs a $14 Billion Fund on Just 11 Stocks. These Are His 3 Biggest Bets Right Now.
- Is Bristol-Myers Squibb Stock Underperforming the Dow?
- Bristol Myers vs. Pfizer: Which High‑Yield Dividend Stock Wins Now?
Mes métriques Votre watchlist personnelle — lignes sélectionnées de Fondamentaux Complets
📊
Choisissez les indicateurs qui vous importent — cliquez sur le ➕ à côté de n'importe quelle ligne dans Fondamentaux Complets ci-dessus.
Votre sélection est enregistrée et vous suit sur tous les tickers.
Détenteurs institutionnels (13F) 2 785 déclarants · $58.1B total · Au 30 juin 2026
Institutions qui déclarent détenir cette action dans leur Formulaire SEC 13F trimestriel. Uniquement les positions longues ; un même déclarant peut apparaître deux fois pour des jambes d'options distinctes. Les jambes put/call compensatoires importantes reflètent généralement la tenue de marché ou un inventaire couvert, pas une conviction directionnelle.
Activité institutionnelle — Q2 2026 vs trimestre précédent
| Nouvelles positions | Positions clôturées | Augmenté | Diminué | Variation nette des actions |
|---|---|---|---|---|
| 159 (-159 vs T. préc.) | 154 (+18 vs T. préc.) | 1 006 (-29 vs T. préc.) | 987 (+89 vs T. préc.) | +55.3M |
Comparé à Q1 2026. Les dépôts de formulaire 13F de la SEC sont dus dans les 45 jours suivant la fin du trimestre, plus une courte période tampon pour les déposants tardifs — les trimestres encore dans cette fenêtre sont ignorés au profit de la paire la plus récente entièrement déclarée.
| Institution | Valeur | Actions | % de 13F suivies | Type |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $7 682 927 263 | 133 337 856 | 13,22% | Actions |
| STATE STREET CORP | $5 900 803 123 | 102 408 940 | 10,15% | Actions |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $3 894 809 793 | 67 594 755 | 6,70% | Actions |
| GEODE CAPITAL MANAGEMENT, LLC | $2 858 273 235 | 49 750 183 | 4,92% | Actions |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $2 700 823 125 | 46 873 015 | 4,65% | Actions |
| NORGES BANK | $2 124 256 834 | 36 866 658 | 3,66% | Actions |
| PRIMECAP MANAGEMENT CO/CA/ | $1 436 115 120 | 24 923 900 | 2,47% | Actions |
| AMERIPRISE FINANCIAL INC | $1 308 030 705 | 22 705 049 | 2,25% | Actions |
| Independent Franchise Partners LLP | $1 255 703 498 | 21 792 841 | 2,16% | Actions |
| DIMENSIONAL FUND ADVISORS LP | $938 463 230 | 16 287 109 | 1,61% | Actions |
| VANGUARD FIDUCIARY TRUST CO | $660 776 941 | 11 467 840 | 1,14% | Actions |
| VICTORY CAPITAL MANAGEMENT INC | $585 933 423 | 10 168 924 | 1,01% | Actions |
| TWO SIGMA INVESTMENTS, LP | $581 119 768 | 10 085 383 | 1,00% | Actions |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $494 716 447 | 8 585 846 | 0,85% | Actions |
| BlackRock, Inc. | $492 399 085 | 8 545 628 | 0,85% | Actions |
| FMR LLC | $451 250 223 | 7 831 486 | 0,78% | Actions |
| TWO SIGMA ADVISERS, LP | $446 094 588 | 8 270 200 | 0,77% | Actions |
| Robeco Institutional Asset Management B.V. | $417 435 581 | 7 244 630 | 0,72% | Actions |
| GOLDMAN SACHS GROUP INC | $392 167 333 | 6 806 097 | 0,67% | Actions |
| FIRST TRUST ADVISORS LP | $344 672 508 | 5 981 822 | 0,59% | Actions |
| Capital International Investors | $340 767 005 | 5 913 752 | 0,59% | Actions |
| Swiss National Bank | $331 822 056 | 5 758 800 | 0,57% | Actions |
| VAN ECK ASSOCIATES CORP | $325 076 944 | 5 641 738 | 0,56% | Actions |
| National Pension Service | $321 412 139 | 5 578 135 | 0,55% | Actions |
| Mitsubishi UFJ Asset Management Co., Ltd. | $319 229 612 | 5 540 268 | 0,55% | Actions |
| BNP PARIBAS FINANCIAL MARKETS | $316 480 270 | 5 492 542 | 0,54% | Actions |
| Legal & General Group Plc | $315 258 552 | 5 471 339 | 0,54% | Actions |
| M&G PLC | $306 949 282 | 5 292 229 | 0,53% | Actions |
| NORDEA INVESTMENT MANAGEMENT AB | $300 773 017 | 5 232 200 | 0,52% | Actions |
| Sumitomo Mitsui Trust Group, Inc. | $293 408 012 | 5 092 121 | 0,50% | Actions |
| ALLIANCEBERNSTEIN L.P. | $288 555 718 | 4 757 720 | 0,50% | Actions |
| Vanguard Global Advisers, LLC | $270 856 466 | 4 700 737 | 0,47% | Actions |
| VANGUARD ASSET MANAGEMENT, Ltd | $266 201 519 | 4 619 950 | 0,46% | Actions |
| California Public Employees Retirement System | $263 375 546 | 4 570 905 | 0,45% | Actions |
| BANK OF AMERICA CORP /DE/ | $263 115 723 | 4 566 396 | 0,45% | Actions |
| VANGUARD GROUP INC | $247 970 649 | 4 597 157 | 0,43% | Actions |
| Caisse de depot et placement du Quebec | $243 646 343 | 4 228 503 | 0,42% | Actions |
| CANADA PENSION PLAN INVESTMENT BOARD | $241 222 903 | 4 186 444 | 0,42% | Actions |
| JANE STREET GROUP, LLC | $224 896 622 | 3 903 100 | 0,39% | Option d'achat |
| WELLINGTON MANAGEMENT GROUP LLP | $214 546 630 | 3 723 475 | 0,37% | Actions |
| Employees Provident Fund Board | $209 755 987 | 3 640 333 | 0,36% | Actions |
| CITADEL ADVISORS LLC | $194 502 072 | 3 375 600 | 0,33% | Option de vente |
| RHUMBLINE ADVISERS | $192 874 042 | 3 347 347 | 0,33% | Actions |
| LPL Financial LLC | $188 151 217 | 3 265 381 | 0,32% | Actions |
| BARCLAYS PLC | $186 163 076 | 3 230 876 | 0,32% | Actions |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $185 255 963 | 3 215 133 | 0,32% | Actions |
| UBS Group AG | $180 243 196 | 3 128 136 | 0,31% | Actions |
| Qube Research & Technologies Ltd | $178 273 860 | 3 093 958 | 0,31% | Actions |
| Artemis Investment Management LLP | $175 941 518 | 3 053 480 | 0,30% | Actions |
| SEB Asset Management AB | $165 520 833 | 2 872 632 | 0,28% | Actions |
| Ensign Peak Advisors, Inc | $165 119 502 | 2 865 663 | 0,28% | Actions |
| CITADEL ADVISORS LLC | $157 769 322 | 2 738 100 | 0,27% | Option d'achat |
| JANE STREET GROUP, LLC | $152 525 902 | 2 647 100 | 0,26% | Option de vente |
| NATIXIS | $145 152 674 | 2 519 137 | 0,25% | Actions |
| AustralianSuper Pty Ltd | $140 209 857 | 2 433 354 | 0,24% | Actions |
| Mirae Asset Global Investments Co., Ltd. | $138 044 440 | 2 395 773 | 0,24% | Actions |
| Bank of New York Mellon Corp | $136 334 163 | 2 366 091 | 0,23% | Actions |
| FORT WASHINGTON INVESTMENT ADVISORS INC /OH/ | $132 803 901 | 2 304 823 | 0,23% | Actions |
| PANAGORA ASSET MANAGEMENT INC | $132 622 456 | 2 301 674 | 0,23% | Actions |
| Capital World Investors | $129 313 224 | 2 244 242 | 0,22% | Actions |
| NEW YORK STATE COMMON RETIREMENT FUND | $129 300 432 | 2 244 020 | 0,22% | Actions |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $125 419 207 | 2 176 661 | 0,22% | Actions |
| RAYMOND JAMES FINANCIAL INC | $123 353 032 | 2 140 802 | 0,21% | Actions |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $122 879 893 | 2 132 591 | 0,21% | Actions |
| PFA Pension, Forsikringsaktieselskab | $121 829 832 | 2 114 367 | 0,21% | Actions |
| VIRGINIA RETIREMENT SYSTEMS ET Al | $120 528 714 | 2 234 496 | 0,21% | Actions |
| MACKENZIE FINANCIAL CORP | $118 944 044 | 2 064 284 | 0,20% | Actions |
| Pictet Asset Management Holding SA | $116 783 155 | 2 026 687 | 0,20% | Actions |
| WORLDQUANT MILLENNIUM ADVISORS LLC | $116 161 574 | 2 015 994 | 0,20% | Actions |
| TD Asset Management Inc | $115 669 154 | 2 007 448 | 0,20% | Actions |
| SUSQUEHANNA ADVISORS GROUP, INC. | $115 240 000 | 2 000 000 | 0,20% | Option d'achat |
| MACQUARIE GROUP LTD | $111 978 478 | 1 943 396 | 0,19% | Actions |
| Vinva Investment Management Ltd | $109 557 913 | 1 870 866 | 0,19% | Actions |
| ENVESTNET ASSET MANAGEMENT INC | $108 509 833 | 1 883 218 | 0,19% | Actions |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $106 751 521 | 1 760 124 | 0,18% | Actions |
| LMR Partners LLP | $106 066 896 | 1 840 800 | 0,18% | Option de vente |
| AVIVA PLC | $103 620 639 | 1 798 345 | 0,18% | Actions |
| PRUDENTIAL FINANCIAL INC | $103 202 606 | 1 791 090 | 0,18% | Actions |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $102 378 000 | 1 776 782 | 0,18% | Actions |
| STOREBRAND ASSET MANAGEMENT AS | $101 037 131 | 1 753 508 | 0,17% | Actions |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $100 790 172 | 1 749 222 | 0,17% | Actions |
| BANK OF NOVA SCOTIA | $99 453 647 | 1 726 026 | 0,17% | Actions |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $98 875 920 | 1 716 000 | 0,17% | Actions |
| KLP KAPITALFORVALTNING AS | $94 673 002 | 1 643 058 | 0,16% | Actions |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $90 576 678 | 1 567 009 | 0,16% | Actions |
| BANK OF MONTREAL /CAN/ | $89 684 378 | 1 556 480 | 0,15% | Actions |
| Douglas Lane & Associates, LLC | $89 667 305 | 1 556 184 | 0,15% | Actions |
| PNC Financial Services Group, Inc. | $89 112 096 | 1 546 548 | 0,15% | Actions |
| Walleye Trading LLC | $88 014 550 | 1 527 500 | 0,15% | Option d'achat |
| Korea Investment CORP | $86 518 389 | 1 501 534 | 0,15% | Actions |
| APG Asset Management N.V. | $85 242 422 | 1 691 386 | 0,15% | Actions |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $85 175 958 | 1 478 236 | 0,15% | Actions |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | $84 205 059 | 1 764 695 | 0,14% | Actions |
| Mariner, LLC | $83 309 670 | 1 445 809 | 0,14% | Actions |
| Retirement Systems of Alabama | $80 928 212 | 1 404 516 | 0,14% | Actions |
| AMERICAN CENTURY COMPANIES INC | $80 695 542 | 1 400 478 | 0,14% | Actions |
| Nuveen Asset Management, LLC | $76 733 142 | 1 356 668 | 0,13% | Actions |
| CWM, LLC | $76 220 909 | 1 256 734 | 0,13% | Actions |
| Eurizon Capital SGR S.p.A. | $70 986 984 | 1 230 296 | 0,12% | Actions |
| Aberdeen Group plc | $70 798 674 | 1 228 717 | 0,12% | Actions |
Initiés de la société 102 initiés · 65 dirigeants · 37 administrateurs
| Dirigeant | Rôle | Dernière activité | Actions détenues | Achats 12m | Ventes 12m | Net 12m |
|---|---|---|---|---|---|---|
| Christopher S. Boerner | Chief Executive Officer | 13 juin 2025 G | 125 439 | 0 | 0 | $0 |
| Peter R Dolan | Former CEO | 8 septembre 2006 F | 571 673 | 0 | 0 | $0 |
| David V Elkins | EVP, Chief Financial Officer | 1 avril 2026 S | 159 248 | 0 | 3 | $-4 500 496 |
| Jean-Marc Huet | EVP & CFO | 30 avril 2009 P | 25 000 | 0 | 0 | $0 |
| Benjamin Hickey | President, RayzeBio Org. | 9 mai 2025 S | 0 | 0 | 0 | $0 |
| Lynelle Hoch | President, Cell Therapy Org. | 10 mars 2025 A | 4 711 | 0 | 0 | $0 |
| James B D Palmer DR | CSO & President, PRI | 2 mars 2004 A | 178 889 | 0 | 0 | $0 |
| Dean J Mitchell | President, U.S. Primary Care | 10 septembre 2003 A | 60 000 | 0 | 0 | $0 |
| Cristian Massacesi | EVP,Chief Med Offr,Head of Dev | 1 août 2026 M | 24 997 | 0 | 0 | $0 |
| Cari Gallman | EVP, General Counsel | 1 août 2026 M | 13 649 | 0 | 0 | $0 |
| Bartie Wendy Short | EVP, Corporate Affairs | 3 juin 2026 F | 12 081 | 0 | 0 | $0 |
| Hiroshi Chris Shibutani | EVP, Chief Strategy Officer | 1 juillet 2025 A | — | 0 | 0 | $0 |
| Adam Lenkowsky | EVP, Chief Commercial Officer | 1 mai 2025 J | 12 439 | 0 | 0 | $0 |
| Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 25 avril 2025 P | 83 513 | 0 | 0 | $0 |
| Karin Shanahan | EVP, Glob. Prod. Dev. & Supply | 1 avril 2025 M | 13 797 | 0 | 0 | $0 |
| Phil M Holzer | SVP and Controller | 10 mars 2025 A | 14 967 | 0 | 0 | $0 |
| Ahn Amanda Poole | EVP, Chief People Officer | 10 mars 2025 A | 5 196 | 0 | 0 | $0 |
| Gregory Scott Meyers | EVP, Chief Digital & Tech Off. | 10 mars 2025 A | 16 102 | 0 | 0 | $0 |
| Robert M Plenge | EVP, Chief Research Officer | 10 mars 2025 A | 15 839 | 0 | 0 | $0 |
| Sandra Leung | EVP, General Counsel | 10 mars 2025 A | 364 296 | 0 | 0 | $0 |
| Giovanni Caforio | Executive Chair of the Board | 10 mars 2024 M | 432 266 | 0 | 0 | $0 |
| Ann Powell Judge | EVP, Chief Human Resources | 24 août 2023 S | 27 868 | 0 | 0 | $0 |
| Michelle Weese | EVP, Corporate Affairs | 1 juillet 2023 M | 3 453 | 0 | 0 | $0 |
| Rupert Vessey | EVP & President, Research | 3 mai 2023 S | 47 751 | 0 | 0 | $0 |
| Sharon Greenlees | SVP & Controller | 2 mai 2023 M | 609 | 0 | 0 | $0 |
| Elizabeth Mily | EVP, Strategy & BD | 1 avril 2023 M | 34 734 | 0 | 0 | $0 |
| Karen Murphy Santiago | SVP & Controller | 14 mars 2022 S | 16 704 | 0 | 0 | $0 |
| Paul Von Autenried | EVP, Chief Information Officer | 24 novembre 2021 S | 63 536 | 0 | 0 | $0 |
| Adam Dubow | SVP,ChiefCompliance&EthicsOff. | 30 juillet 2021 S | 13 777 | 0 | 0 | $0 |
| Joseph Eid | SVP,Head Glob. Medical Affairs | 3 juin 2021 M | 9 485 | 0 | 0 | $0 |
| Louis S Schmukler | EVP,Pres.,Glob.Prod. & Supply | 10 mai 2021 S | 31 956 | 0 | 0 | $0 |
| Kathryn Metcalfe | EVP, Corporate Affairs | 10 mars 2020 A | — | 0 | 0 | $0 |
| John E Elicker | EVP, Investor Relations | 10 mars 2020 M | 70 946 | 0 | 0 | $0 |
| Charles A Bancroft | EVP, Head of Integration | 10 mars 2020 M | 137 534 | 0 | 0 | $0 |
| Paul Biondi | SVP, Head of Strategy & BD | 2 octobre 2019 M | 6 214 | 0 | 0 | $0 |
| Thomas J. Lynch Jr. | EVP & Chief Scientific Officer | 3 avril 2019 M | 22 223 | 0 | 0 | $0 |
| Murdo Gordon | EVP, Chief Commercial Officer | 1 août 2018 M | 49 424 | 0 | 0 | $0 |
| Joseph C Caldarella | SVP & Controller | 6 septembre 2017 S | 46 297 | 0 | 0 | $0 |
| Anne Nielsen | Chief Compliance & Ethics Off | 3 septembre 2017 M | 37 974 | 0 | 0 | $0 |
| Emmanuel Blin | SVP, Chief Strategy Officer | 10 mars 2017 A | 20 138 | 0 | 0 | $0 |
| Francis M Cuss | EVP & CSO | 10 mars 2017 M | 321 906 | 0 | 0 | $0 |
| Samuel J Moed | SVP, Strat Plan & Analysis | 13 mars 2015 S | 31 015 | 0 | 0 | $0 |
| Brian Daniels | SVP Global Dev & Med Affairs | 1 juillet 2014 M | 94 374 | 0 | 0 | $0 |
| Frances K Heller | SVP, Business Development | 10 mars 2014 A | 4 174 | 0 | 0 | $0 |
| Elliot Sigal | EVP, CSO & President R&D | 3 juin 2013 M | 148 221 | 0 | 0 | $0 |
| Beatrice J Cazala | EVP Commercial Operations | 31 mai 2013 S | 173 375 | 0 | 0 | $0 |
| John E Celentano | SVP HR Public Affairs & Philan | 6 mars 2012 M | 142 142 | 0 | 0 | $0 |
| Jeremy M Levin | SVP Strat Transactions | 1 octobre 2011 M | 43 689 | 0 | 0 | $0 |
| De Notaristefani Carlo | Pres Tech Ops & Supp Fnctns | 14 juin 2011 M | 7 578 | 0 | 0 | $0 |
| Anthony C Hooper | SVP ComOps Pres USJap Int | 13 mai 2011 M | 203 170 | 0 | 0 | $0 |
Initiés issus des déclarations SEC Form 3/4/5 ; net = uniquement P/S de marché
Activistes et détenteurs de 5%+ 11 participations
Investisseurs ayant déposé un Schedule 13D auprès de la SEC — détention effective supérieure à 5% avec l'intention d'influencer l'émetteur (participations activistes, campagnes pour le conseil d'administration, fusions-acquisitions). Chaque ligne montre le dernier état connu de la position du déposant.
| Déclarant | Déposé | Participation | Statut | Objectif | Dépôt |
|---|---|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY, CELGENE CORPORATION ×3 dépôts | 16 juillet 2020 | — | Dépôt initial | — | SEC |
| Wellington Management Group LLP, Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP, Wellington Management Company LLP | 27 février 2019 | — | Dépôt initial | Investissement passif | SEC |
| S.S. OR ×3 dépôts | 23 décembre 2009 | — | Dépôt initial | — | SEC |
| Medarex, Inc. S.S. OR, S.S. OR | 25 novembre 2009 | — | Dépôt initial | — | SEC |
| Identification Nos. of Above Persons (entities only) Bristol-Myers Squibb Company ×2 dépôts | 27 février 2009 | — | Dépôt initial | — | SEC |
| Bristol -Myers Squibb Company, Bristol -Myers Squibb Biologics Company ×3 dépôts | 8 octobre 2008 | — | Dépôt initial | — | SEC |
| Bristol-Myers Squibb Company I.R.S. Employer Identification Number 22-079-0350 ×3 dépôts | 6 juin 2003 | — | Dépôt initial | — | SEC |
| Personne déclarante non divulguée | 16 avril 2003 | — | Dépôt initial | — | SEC |
| Personne déclarante non divulguée | 3 février 2003 | — | Dépôt initial | — | SEC |
| Personne déclarante non divulguée | 6 mars 2002 | — | Dépôt initial | — | SEC |
| Personne déclarante non divulguée | 6 février 2002 | — | Dépôt initial | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Détention d'ETF Détenu par 296 ETFs
Le poids reflète uniquement les participations directes en actions (N-PORT) ; les fonds à effet de levier ou basés sur des dérivés peuvent détenir une exposition supplémentaire aux swaps non indiquée.
| Fonds | Poids | Unités | Au | Source |
|---|---|---|---|---|
| FTXH · First Trust Exchange-Traded Fund VI | 6,29% | 39 590 NS | 30 juin 2026 | N-PORT |
| RDIV · Invesco Exchange-Traded Fund Trust … | 5,25% | 1 134 150 SH | 21 août 2026 | Quotidien |
| ROPE · EA Series Trust | 4,97% | 7 379 NS | 29 mai 2026 | N-PORT |
| IHE · iShares Trust | 4,65% | 1 223 984 SH | 21 août 2026 | Quotidien |
| CAMX · ADVISORS' INNER CIRCLE FUND | 4,10% | 44 768 NS | 30 avril 2026 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 3,50% | 6 427 NS | 30 avril 2026 | N-PORT |
| FDL · First Trust Exchange-Traded Fund | 3,43% | 4 337 329 NS | 30 juin 2026 | N-PORT |
| CANC · Tema ETF Trust | 3,30% | 101 680 NS | 31 mai 2026 | N-PORT |
| ABOT · Abacus FCF ETF Trust | 3,21% | 2 332 NS | 30 avril 2026 | N-PORT |
| AGNG · Global X Funds | 2,98% | 42 594 NS | 31 mai 2026 | N-PORT |
| SCHD · SCHWAB STRATEGIC TRUST | 2,93% | 48 641 121 NS | 31 mai 2026 | N-PORT |
| PJP · Invesco Exchange-Traded Fund Trust | 2,78% | 224 546 SH | 21 août 2026 | Quotidien |
| ABFL · Abacus FCF ETF Trust | 2,76% | 226 688 NS | 30 avril 2026 | N-PORT |
| HDV · iShares Trust | 2,62% | 6 134 190 SH | 21 août 2026 | Quotidien |
| ACEP · EA Series Trust | 2,52% | 44 211 NS | 29 mai 2026 | N-PORT |
| SIXH · EXCHANGE TRADED CONCEPTS TRUST | 2,47% | 234 394 NS | 31 mai 2026 | N-PORT |
| SIXA · EXCHANGE TRADED CONCEPTS TRUST | 2,47% | 210 030 NS | 31 mai 2026 | N-PORT |
| VALQ · AMERICAN CENTURY ETF TRUST | 2,45% | 148 728 NS | 31 mai 2026 | N-PORT |
| GEND · Spinnaker ETF Series | 2,18% | 1 612 NS | 30 avril 2026 | N-PORT |
| UPGD · Invesco Exchange-Traded Fund Trust | 2,10% | 38 747 SH | 21 août 2026 | Quotidien |
| HRTS · Tema ETF Trust | 2,09% | 18 939 NS | 31 mai 2026 | N-PORT |
| FDIV · EA Series Trust | 2,07% | 24 896 NS | 30 avril 2026 | N-PORT |
| IYH · iShares Trust | 2,06% | 1 218 183 SH | 21 août 2026 | Quotidien |
| SPHD · Invesco Exchange-Traded Fund Trust … | 2,06% | 1 086 835 SH | 21 août 2026 | Quotidien |
| GCOW · Pacer Funds Trust | 2,03% | 1 123 894 NS | 30 avril 2026 | N-PORT |
| COWZ · Pacer Funds Trust | 2,03% | 6 082 360 NS | 30 avril 2026 | N-PORT |
| QQWZ · Pacer Funds Trust | 2,03% | 15 628 NS | 30 avril 2026 | N-PORT |
| SPDV · ETF Series Solutions | 2,02% | 30 055 NS | 30 avril 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 1,99% | 938 456 NS | 30 avril 2026 | N-PORT |
| VLLU · Harbor ETF Trust | 1,98% | 1 422 NS | 30 avril 2026 | N-PORT |
| BMVP · Invesco Exchange-Traded Fund Trust | 1,93% | 31 120 SH | 21 août 2026 | Quotidien |
| PEY · Invesco Exchange-Traded Fund Trust | 1,83% | 327 924 SH | 21 août 2026 | Quotidien |
| SDOG · ALPS ETF Trust | 1,83% | 441 820 NS | 31 mai 2026 | N-PORT |
| RFDA · ALPS ETF Trust | 1,82% | 27 812 NS | 31 mai 2026 | N-PORT |
| CURE · Direxion Shares ETF Trust | 1,78% | 40 606 NS | 30 avril 2026 | N-PORT |
| FLOW · Global X Funds | 1,78% | 8 912 NS | 31 mai 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 1,73% | 6 137 665 SH | 19 août 2026 | Quotidien |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,70% | 213 437 SH | 21 août 2026 | Quotidien |
| RXL · ProShares Trust | 1,68% | 21 228 NS | 31 mai 2026 | N-PORT |
| GMOV · GMO ETF Trust | 1,66% | 26 358 NS | 31 mai 2026 | N-PORT |
| VMAX · Lattice Strategies Trust | 1,65% | 12 671 NS | 30 avril 2026 | N-PORT |
| IXJ · iShares Trust | 1,61% | 1 073 117 SH | 21 août 2026 | Quotidien |
| NULV · Nushares ETF Trust | 1,57% | 539 514 NS | 30 avril 2026 | N-PORT |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1,54% | 13 556 NS | 30 avril 2026 | N-PORT |
| NUDV · Nushares ETF Trust | 1,54% | 11 473 NS | 30 avril 2026 | N-PORT |
| PWV · Invesco Exchange-Traded Fund Trust | 1,47% | 415 736 SH | 21 août 2026 | Quotidien |
| COWG · Pacer Funds Trust | 1,47% | 526 151 NS | 30 avril 2026 | N-PORT |
| REVS · Columbia ETF Trust I | 1,46% | 68 134 NS | 30 avril 2026 | N-PORT |
| TMFE · RBB Fund, Inc. | 1,45% | 21 473 NS | 31 mai 2026 | N-PORT |
| FCPI · FIDELITY COVINGTON TRUST | 1,43% | 64 178 NS | 30 avril 2026 | N-PORT |